Systemic Lupus Erythematosus Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeu

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Systemic Lupus Erythematosus pipeline constitutes 55+ key companies continuously working towards developing 60+ Systemic Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Systemic Lupus Erythematosus Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report: https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years.
• Systemic Lupus Erythematosus companies working in the treatment market are Roche, Equillium/ Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, I-Mab Biopharma, Pfizer, InnoCare Pharma, Bristol Myers Squibb, Sanofi, Eli Lilly and Company, Hoffman-La-Roche, ImmuPharma, and others, are developing therapies for the Systemic Lupus Erythematosus treatment
• Emerging Systemic Lupus Erythematosus therapies in the different phases of clinical trials are- Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, TJ202, PF-06835375, ICP-022, Deucravacitinib, SAR441344, Baricitinib, Obinutuzumab, Forigerimod, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.
• On February 1, 2022, Mosunetuzumab development and commercialization participant option was exercised, according to a statement from Biogen Inc. As part of their long-standing partnership on CD20 antibody development, Biogen and Genentech, a member of the Roche Group, will jointly pay a $30 million one-time option fee. For those with SLE, mosunetuzumab is currently in the Phase Ib stage of development.
• In June 2021, A Phase II randomised, double-blind, placebo-controlled effectiveness and safety research of VIB7734 was started by Viela Bio (a subsidiary of Horizon Therapeutics) for the treatment of moderately to severely active Systemic Lupus Erythematosus in about 195 people.

Systemic Lupus Erythematosus Overview
Systemic lupus erythematosus (SLE) is a chronic, multisystemic autoimmune disease that has a high morbidity and mortality rate. Loss of immunological tolerance to self-antigens is influenced by genetic, immunological, endocrine, and environmental variables, which results in the development of pathogenic autoantibodies that harm tissue by a variety of ways.

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:
• Mosunetuzumab: Roche
• Itolizumab: Equillium/ Biocon Limited
• KPG 818: Kangpu Biopharmaceuticals
• BOS161721: Boston Pharmaceuticals
• NKTR-358: Nektar Therapeutics
• ABBV-599: AbbVie
• Daxdilimab (VIB7734): Horizon Therapeutics
• SAR441344: Sanofi
• BIIB059: Biogen
• Obinutuzumab: Hoffman-La-Roche
• TJ202: I-Mab Biopharma
• PF-06835375: Pfizer
• ICP-022: InnoCare Pharma
• BOS161721: Boston Pharmaceuticals
• Deucravacitinib: Bristol Myers Squibb
• SAR441344: Sanofi
• Baricitinib: Eli Lilly and Company
• Obinutuzumab: Hoffman-La-Roche
• Forigerimod: ImmuPharma
• Dapirolizumab pegol: UCB
• PRV 3279: Provention Bio

Systemic Lupus Erythematosus Route of Administration
Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Systemic Lupus Erythematosus Molecule Type
Systemic Lupus Erythematosus Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment
• Systemic Lupus Erythematosus Assessment by Product Type
• Systemic Lupus Erythematosus By Stage and Product Type
• Systemic Lupus Erythematosus Assessment by Route of Administration
• Systemic Lupus Erythematosus By Stage and Route of Administration
• Systemic Lupus Erythematosus Assessment by Molecule Type
• Systemic Lupus Erythematosus by Stage and Molecule Type

DelveInsight's Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies at:
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:
Key companies developing therapies for Systemic Lupus Erythematosus are - AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Systemic Lupus Erythematosus Pipeline Analysis:
The Systemic Lupus Erythematosus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
• Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies-
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Systemic Lupus Erythematosus Pipeline Market Drivers
• Promising Therapeutic Approaches, Increasing Awareness of the Disease, Recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

Systemic Lupus Erythematosus Pipeline Market Barriers
• However, obstacles in SLE Pipeline, hit and Trial Approach of Researchers, high Annual Cost of Therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight
• Coverage: Global
• Key Systemic Lupus Erythematosus Companies: Roche, Equillium/ Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, I-Mab Biopharma, Pfizer, InnoCare Pharma, Bristol Myers Squibb, Sanofi, Eli Lilly and Company, Hoffman-La-Roche, ImmuPharma, and others
• Key Systemic Lupus Erythematosus Therapies: Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, TJ202, PF-06835375, ICP-022, Deucravacitinib, SAR441344, Baricitinib, Obinutuzumab, Forigerimod, and others
• Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
• Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Systemic Lupus Erythematosus Report Introduction
2. Systemic Lupus Erythematosus Executive Summary
3. Systemic Lupus Erythematosus Overview
4. Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment
5. Systemic Lupus Erythematosus Pipeline Therapeutics
6. Systemic Lupus Erythematosus Late Stage Products (Phase II/III)
7. Systemic Lupus Erythematosus Mid Stage Products (Phase II)
8. Systemic Lupus Erythematosus Early Stage Products (Phase I)
9. Systemic Lupus Erythematosus Preclinical Stage Products
10. Systemic Lupus Erythematosus Therapeutics Assessment
11. Systemic Lupus Erythematosus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Systemic Lupus Erythematosus Key Companies
14. Systemic Lupus Erythematosus Key Products
15. Systemic Lupus Erythematosus Unmet Needs
16 . Systemic Lupus Erythematosus Market Drivers and Barriers
17. Systemic Lupus Erythematosus Future Perspectives and Conclusion
18. Systemic Lupus Erythematosus Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Systemic Lupus Erythematosus Market
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Systemic Lupus Erythematosus-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Systemic Lupus Erythematosus Epidemiology https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Systemic Lupus Erythematosus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.